Clinical Trial Search

Primary: Percentage of Participants (Defined as Estimated Cumulative Control Rate) Reaching Blood Pressure Target in a Stepped Care, Aliskiren-based Regimen — 86.12 Percentage of…

Primary: The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal…

Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg

Primary: SBP — 130.2; 128.8 mm Hg

Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg

Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants

Primary: Unadjusted and Adjusted Changes From Baseline in Systolic and Diastolic Blood Pressure at Weeks 1, 3, 6 — -1.2; -5.3; 0.8; -1.7 mmHg

Primary: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint — -10.3; -6.6 mmHg

Primary: Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring — -21.4 mm Hg — p=<0.0001

Primary: Aortic Systolic Blood Pressure (SBP) — 112.7; 107.7; 106.2; 106.6 mm Hg

Primary: Change From Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) to Week 7 — -28.5; -37.0 mmHg — p=<0.0001

Primary: Change From Baseline in Mean Daytime Systolic Blood Pressure (SBP) as Measured by Ambulatory Blood Pressure Monitoring (ABPM) at Day 28 — 1.38; -1.42; -3.28; -5.59…

Primary: Change From Baseline to Day 10 in 24-hour Mean Ambulatory Systolic Blood Pressure (SBP) — -0.47; -2.49 mmHg

Primary: Change in Oral Glucose Tolerance Test (OGTT) Area Under Curve (AUC) After Addition of Trandolapril to Hydrochlorothiazide (HCTZ) Compared With Change in OGTT AUC After…

Primary: Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg — -6.1; -7.1; -8.9 mm Hg — p=0.1187

Primary: Change in Mean Systolic Blood Pressure (SBP) — -10.58; -4.65 mmHg — p=<0.0001

Primary: Change in Resting vs. Peak Heart Rate Systolic Blood Pressure (SBP) From Baseline to Week 8 After a Missed Dose — 2.58; 8.26 mmHg

Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg

Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg

Primary: Systolic Blood Pressure — 128.99; 131.4; 131.21; 127.45 mm Hg

Primary: Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 — 99.2; -12.7 mm Hg — p=<0.05

Primary: Composite Adverse Perinatal Outcome — 353; 427; 272; 336 Participants — p=<0.001

Primary: Change in Mean Trough Sitting Diastolic Blood Pressure — -11.16; -10.45 mm Hg — p=0.2648

Primary: Mobility - Measured by Change in Gait Speed — 0.4; 0.42 seconds

Primary: Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy) — 38 Participants

Primary: Number of Participants Who Measured Blood Pressure as Instructed (Assessed on Questionnaire) — 34; 47; 50 Participants — p==0.05

Primary: Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo — -4.10; -11.3; -11.07; -5.63 mmHg

Primary: Comparative Performance of Clinic, Home, and Kiosk — -4.7; -0.1; 9.5; -7.2 millimeters of mercury — p=<0.05

Primary: Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16 — -11.16; -9.13; -8.10; -5.66 mm Hg — p=<0.0001

Primary: Pregnancy Loss or NICU Admission for Greater Than 48 Hours — 155; 150 participants